Loading clinical trials...
Loading clinical trials...
Prospective Multicenter Clinical Study of Venetoclax Combined With Hypomethylating Agents and Subcutaneous Cytarabine in Induction Therapy for CEBPA-Mutated Acute Myeloid Leukemia
Conditions
Interventions
Venetoclax + Hypomethylating Agents + Low-Dose Cytarabine for CEBPA-Mutated AML (Unfit Patients)
Locations
1
China
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
Start Date
September 15, 2025
Primary Completion Date
September 1, 2027
Completion Date
December 1, 2027
Last Updated
March 5, 2026
NCT05768932
NCT06660368
NCT05143996
NCT07198867
NCT06398457
NCT07023588
Lead Sponsor
The First Affiliated Hospital of Soochow University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions